SCHEMBL2860980

SCHEMBL2860980

CC(C)(C)c1ccc(Cc2ccc(O)c(CP(=O)(O)O)c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 1/20 0.41
THRB P10828 1/20 0.41
CYP2D6 P10635 3/20 0.41
ANPEP P15144 1/20 0.41
ERAP2 Q6P179 1/20 0.41
EGFR P00533 1/20 0.41
EPHX2 P34913 2/20 0.40
NR1H4 Q96RI1 2/20 0.40
ESRRG P62508 2/20 0.40
PGK1 P00558 1/20 0.39
PGK2 P07205 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
SIRT1 Q96EB6 1/20 0.38
PLG P00747 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2868577 0.84 THRA (0.50) THRATHRBEGFRPGK1PGK2
SCHEMBL2874053 0.79 THRA (0.52) THRATHRBALDH1A1HPGDALOX15
SCHEMBL2865155 0.76 SLC5A1 (0.48) ANPEPERAP2EPHX2NR1H4ESRRG
SCHEMBL5037236 0.76 PGK1 (0.61) ANPEPERAP2EPHX2NR1H4ESRRG
SCHEMBL2868009 0.75 ALOX5 (0.50) THRATHRBEGFR
SCHEMBL7751737 0.75 ESR1 (0.44) CYP2D6ESRRGALDH1A1HPGDALOX15
SCHEMBL7095183 0.73 ALDH1A1 (0.50) CYP2D6ESRRGALDH1A1HPGDALOX15
SCHEMBL10756797 0.72 CYP2D6 (0.55) CYP2D6ALDH1A1HPGDALOX15HSD17B10
SCHEMBL2869183 0.72 THRA (0.47) THRATHRBEGFRPGK1PGK2
SCHEMBL2869960 0.71 THRA (0.49) THRATHRBALDH1A1HPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691898-B2 Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2010-04-06 US disclosed
US-20080119441-A1 Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
CN-101072783-A Phosphonic acid derivative and therapeutic agent for disease in which high phosphate level in blood participates KOTOBUKI PHARMACEUTICAL CO LTD (JP) 2007-11-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119441-A1 Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia NR0B1, NR0B2, PTH1R THRA 582/4885THRB 544/4885CYP2D6 2173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.